ArticlePloS one2017
Lipoxin A4 encapsulated in PLGA microparticles accelerates wound healing of skin ulcers.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Immuno-metabolic dysregulation in type 2 diabetes is associated with altered neutrophil functional plasticity, mitochondrial dysfunction, and compromised responses in sepsis.Journal of translational medicine · 2026Article
- Effects triggered by tumor necrosis factor-α in immortalized murine dental pulp and pre-osteoblastic cells.Brazilian oral research · 2025Article
- A mouse protozoan boosts antigen-specific mucosal IgA responses in a specific lipid metabolism- and signaling-dependent manner.Nature communications · 2024Article
- Biomaterials for immunomodulation in wound healing.Regenerative biomaterials · 2024Review
- The Use of Specialized Pro-Resolving Mediators in Biomaterial-Based Immunomodulation.Journal of functional biomaterials · 2023Review
- Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of In Vitro and In Vivo Studies.International journal of molecular sciences · 2023Review
- Immunoengineering strategies to enhance vascularization and tissue regeneration.Advanced drug delivery reviews · 2022Review
- Leukotriene BBMC oral health · 2022Article
- Porcine Fibrin Sealant Promotes Skin Wound Healing in Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
- Role of arachidonic cascade in COVID-19 infection: A review.Prostaglandins & other lipid mediators · 2021Review
- Eicosanoids in Skin Wound Healing.International journal of molecular sciences · 2020Review
- Lipoxin suppresses inflammation via the TLR4/MyD88/NF-κB pathway in periodontal ligament cells.Oral diseases · 2020Article
- The Role of Lipidomics in Autism Spectrum Disorder.Molecular diagnosis & therapy · 2020Review
- Repair Process Impairment byFrontiers in cellular and infection microbiology · 2019Review
- Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases.International journal of molecular sciences · 2018Review
- Arachidonic acid: Physiological roles and potential health benefits - A review.Journal of advanced research · 2018Review
- Leukotriene B4 Loaded in Microspheres Inhibits Osteoclast Differentiation and Activation.Brazilian dental journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoxin A4 (LXA4) is involved in the resolution of inflammation and wound healing; however, it is extremely unstable. Thus, to preserve its biological activities and confer stability, we encapsulated LXA4 in poly-lactic-co-glycolic acid (PLGA) microparticles (LXA4-MS) and assessed its application in treating dorsal rat skin lesions. Ulcers were sealed with fibrin adhesive and treated with either LXA4-MS, unloaded microparticles (Un-MS), soluble LXA4, or PBS/glue (vehicle). All groups were compared at 0, 2, 7, and 14 days post-lesions. Our results revealed that LXA4-MS accelerated wound healing from day 7 and reduced initial ulcer diameters by 80%. Soluble LXA4, Un-MS, or PBS closed wounds by 60%, 45%, and 39%, respectively. LXA4-MS reduced IL-1β and TNF-α, but increased TGF-β, collagen deposition, and the number of blood vessels. Compared to other treatments, LXA4-MS reduced inflammatory cell numbers, myeloperoxidase (MPO) concentration, and metalloproteinase-8 (MMP8) mRNA in scar tissue, indicating decreased neutrophil chemotaxis. In addition, LXA4-MS treatment increased macrophages and IL-4, suggesting a positive impact on wound healing. Finally, we demonstrated that WRW4, a selective LXA4 receptor (ALX) antagonist, reversed healing by 50%, indicating that LXA4 must interact with ALX to induce wound healing. Our results show that LXA4-MS could be used as a pharmaceutical formulation for the treatment of skin ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.